Antipsychotic drugs and their side effects
Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most diverse and rapidly changing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiol...
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
London u.a.
Acad. Press
1993
|
| Schriftenreihe: | Neuroscience perspectives
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV009652957 | ||
| 003 | DE-604 | ||
| 005 | 19940614 | ||
| 007 | t| | ||
| 008 | 940614s1993 xx d||| |||| 00||| engod | ||
| 020 | |a 0120790351 |9 0-12-079035-1 | ||
| 035 | |a (OCoLC)29762112 | ||
| 035 | |a (DE-599)BVBBV009652957 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 |a DE-578 | ||
| 050 | 0 | |a RM333.5 | |
| 082 | 0 | |a 615/.788 |2 20 | |
| 082 | 0 | |a 615.5 |2 12a | |
| 084 | |a XI 5820 |0 (DE-625)153018:12926 |2 rvk | ||
| 245 | 1 | 0 | |a Antipsychotic drugs and their side effects |c ed. by Thomas R. E. Barnes |
| 264 | 1 | |a London u.a. |b Acad. Press |c 1993 | |
| 300 | |a XVI, 287 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Neuroscience perspectives | |
| 520 | 3 | |a Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most diverse and rapidly changing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological and therapeutic aspects of chosen research areas | |
| 520 | |a Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including movement disorders like parkinsonism and akathisia; although, in many cases, these can be minimised by titration to the minimum effective dose | ||
| 520 | |a However, the introduction of the atypical neuroleptic, clozapine, with a lower liability for motor side-effects, and efficacy for both positive and negative symptoms in patients unresponsive to conventional neuroleptics raised expectations of effective medication with fewer adverse effects. Further, with the identification and characterization of multiple dopamine receptors, the possibility of more selective drugs with an inherently better side-effect potential has arisen | ||
| 650 | 7 | |a Antipsicóticos (aplicações terapêuticas) |2 larpcal | |
| 650 | 7 | |a Antipsicóticos (farmacologia) |2 larpcal | |
| 650 | 7 | |a Antipsychotische geneesmiddelen |2 gtt | |
| 650 | 7 | |a Bijwerkingen |2 gtt | |
| 650 | 7 | |a Drogas de abuso (complicações) |2 larpcal | |
| 650 | 7 | |a Drogas de abuso (efeitos) |2 larpcal | |
| 650 | 4 | |a Antipsychotic Agents |x adverse effects | |
| 650 | 4 | |a Antipsychotic Agents |x pharmacology | |
| 650 | 4 | |a Antipsychotic Agents |x therapeutic use | |
| 650 | 4 | |a Psychotropic drugs |x Complications | |
| 650 | 4 | |a Psychotropic drugs |x Side effects | |
| 650 | 0 | 7 | |a Psychopharmakon |0 (DE-588)4047729-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Psychopharmakon |0 (DE-588)4047729-0 |D s |
| 689 | 0 | 1 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Barnes, Thomas R. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006382324&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-006382324 | |
Datensatz im Suchindex
| DE-BY-UBM_katkey | 1330401 |
|---|---|
| DE-BY-UBM_media_number | 99994119237 |
| _version_ | 1823050924255346688 |
| adam_text | ANTIPSYCHOTIC DRUGS AND THEIR SIDE-EFFECTS EDITED BY THOMAS R.E. BARNES
DEPARTMENT OF PSYCNIATRY, CHARING CROSS AND WESTMINSTER MEDICAL SCHOOL,
LONDON, UK ACADEMIC PRESS HARCOURT BRACE & COMPANY, PUBLISHERS LONDON
SAN DIEGO NEW YORK BOSTON SYDNEY TOKYO TORONTO CONTENTS CONTRIBUTORS XI
SERIES PREFACE XIII NEUROSCIENCE EDITORIAL ADVISORY BOARD XV PREFACE XVI
PART I: BASIC SCIENCE 1 1 THE PHARMACOLOGY OF THE PHENOTHIAZINES,
BUTYROPHENONES, 3 THIOXANTHINES AND DIPHENYLBUTYLPIPERIDINES B.E.
LEONARD 1.1 INTRODUCTION 3 1.2 EFFECTS OF NEUROLEPTICS ON DOPAMINERGIC
AND OTHER NEUROTRANSMITTER SYSTEMS 5 1.3 HETEROGENEITY OF DOPAMINERGIC
NEURONS IN THE MESOCORTICAL SYSTEM 8 1.4 INTERACTION OF NEUROLEPTICS
WITH NON-DOPAMINERGIC RECEPTORS 11 1.5 ACTION OF NEUROLEPTICS ON
DIFFERENT TYPES OF NEUROTRANSMITTER RECEPTOR 12 1.6 STRUCTURE-ACTIVITY
RELATIONSHIPS AND PHARMACOKINETIC ASPECTS 13 1.7 BEHAVIOURAL AND
PHARMACOLOGICAL PROPERTIES OF THE NEUROLEPTICS 17 1.8 CLINICAL
PHARMACOLOGY OF THE NEUROLEPTICS 21 1.9 HORMONAL CHANGES RESULTING FROM
NEUROLEPTIC TREATMENT 22 1.10 CONCLUSION 23 2 THE PHARMACOLOGY OF
DOZAPINE-LIKE ATYPICAL ANTIPSYCHOTICS 27 DM. COWARD 2.1 INTRODUCTION 27
CONTENTS 2.2 NEUROLEPTIC-LIKE PROPERTIES IN ANIMAL STUDIES 30 2.3
ATYPICAL PROPERTIES OF CLOZAPINE 31 2.4 NEUROTRANSMITTER INTERACTIONS OF
CLOZAPINE AND RELATED AGENTS 33 2.5 MECHANISMS UNDERLYING CLOZAPINE S
ATYPICALITY 35 2.6 CONCLUSIONS 41 2.7 SUMMARY 41 PHARMACOLOGY AND
CLINICAL PROPERTIES OF SELECTIVE DOPAMINE 45 ANTAGONISTS WITH FOCUS ON
SUBSTITUTED BENZAMIDES JES GERLACH 3.1 INTRODUCTION 45 3.2 ANTAGONISM OF
DOPAMINE RECEPTORS 47 3.3 CONCLUSION AND FUTURE TRENDS 59 PRE- AND
POSTSYNAPTIC D, TO D 5 DOPAMINE RECEPTOR MECHANISMS 65 IN RELATION TO
ANTIPSYCHOTIC ACTIVITY JOHN L. WADDINGTON 4.1 PHARMACOLOGICAL
CHARACTERISTICS OF DOPAMINE RECEPTOR SUBTYPES 66 4.2 DJ RECEPTOR
ANTAGONISTS AS PUTATIVE ANTIPSYCHOTIC AGENTS 69 4.3 SELECTIVE D 2
AUTORECEPTOR AGONISTS, ANTAGONISTS AND PARTIAL AGONISTS AS PUTATIVE
ANTIPSYCHOTIC AGENTS 76 4.4 *- IMPLICATIONS FOR THE DOPAMINE HYPOTHESIS
OF SCHIZOPHRENIA 81 PREDICTION OF ANTIPSYCHOTIC ACTIVITY 87 NADIA M.J.
RUPNIAK AND SUSAN D. IVERSEN 5.1 INTRODUCTION 87 5.2 PRECLINICAL SCREENS
FOR ANTIPSYCHOTIC DRUGS 88 5.3 DESIRABLE PRECLINICAL PROFILE USING
DOPAMINE ANTAGONIST SCREENS 89 5.4 PRECLINICAL PROFILES OF NOVEL AGENTS
SUGGESTING ANTIPSYCHOTIC ACTIVITY 90 5.5 DISCUSSION AND TARGETS FOR
FUTURE RESEARCH 94 EFFECTS OF NEUROLEPTICS ON NEURONAL AND SYNAPTIC
STRUCTURE 99 P.]. HARRISON 6.1 NEUROLEPTIC EFFECTS ON NEURONS 100 6.2
NEUROLEPTIC EFFECTS ON SYNAPSES 104 VI CONTENTS 6.3 NEUROLEPTIC EFFECTS
IN HUMAN BRAIN 106 6.4 NEUROLEPTICS AND GENE EXPRESSION 108 BRAIN
IMAGING AND ANTIPSYCHOTIC DRUGS 111 P.F. LIDDLE 7.1 INTRODUCTION 112 7.2
BRAIN-IMAGING TECHNIQUES . 113 7.2 BRAIN-IMAGING TECHNIQUES 7.3 EFFECTS
OF ANTIPSYCHOTIC DRUGS ON BRAIN ACTIVITY 7.4 OCCUPATION OF
NEURORECEPTORS BY ANTIPSYCHOTIC DRUGS 7.5 CONCLUSIONS REGARDING
ANTIPSYCHOTIC DRUG ACTION 122 124 PHARMACOKINETICS OF ANTIPSYCHOTIC
DRUGS 127 S.H. CURRY 8.1 INTRODUCTION 127 8.2 ANALYTICAL METHODS 128 8.3
NEUROLEPTIC DRUG METABOLITES 130 8.4 PRESYSTEMIC ELIMINATION (FIRST-PASS
EFFECT) 131 8.5 ENZYME INDUCTION 133 8.6 BINDING TO PLASMA PROTEIN 133
8.7 PH-DEPENDENT PHENOMENA 134 8.8 ELIMINATION HALF-LIFE 134 8.9
U-SHAPED CLINICAL-CHEMICAL RELATIONSHIPS 135 8.10 CHANGEOVER FROM ORAL
MEDICATION TO DEPOT NEUROLEPTICS 138 -8.11 PROLACTIN 139 8.12
THERAPEUTIC MONITORING 139 -8.13 CONCLUSION 141 PART II: CLINICAL ISSUES
145 9 THE ASSESSMENT OF ANTIPSYCHOTIC MEDICATION IN CLINICAL TRIALS 147
S.R. HIRSCH 9.1 INTRODUCTION 147 9.2 PHASE I STUDIES 148 9.3 PHASE II
STUDIES 148 9.4 PHASE III STUDIES 150 9.5 PHASE IV STUDIES 150 9.6
FIXED- VERSUS FLEXIBLE-DOSE STUDIES 150 9.7 PATIENT SELECTION 151 9.8
STATISTICAL ASPECTS 152 9.9 RATING INSTRUMENTS . 153 CONTENTS 9.10
CLINICAL DESIGNS FOR SPECIFIC PURPOSES 153 9.11 OTHER MEASURES OF
PHARMACOLOGICAL EFFICACY 155 9.12 CONCLUSION 155 10 INDICATIONS FOR
ANTIPSYCHOTIC DRUGS 157 R.G. MCCREADIE 157 163 163 164 164 165 11 ACUTE
TREATMENT 169 10.1 10.2 10.3 10.4 10.5 10.6 ACUTE J.M. 11.1 11.2 11.3
11.4 11.5 11.6 11.7 11.8 SCHIZOPHRENIA MANIA DELUSIONAL DEPRESSION
FUNCTIONAL PSYCHOSIS DEMENTIA MISCELLANEOUS INDICATIONS TREATMENT KANE
INTRODUCTION INDICATIONS CHOICE OF DRUG DOSAGE ANTIPSYCHOTIC DRUG DOSAGE
EQUIVALENCIES STRATEGIES FOR TREATING NON-RESPONSIVE PATIENTS CLOZAPINE
CONCLUSIONS 169 171 171 174 176 177 178 180 12 MAINTENANCE ANTIPSYCHOTIC
MEDICATION 183 J.M. DAVIS, P.G. JANICAK, A. SINGLA AND R.P. SHARMA 12.1
INTRODUCTION 183 12.2 TIME-COURSE OF RELAPSE 186 12.3 INDICATIONS FOR
MAINTENANCE 190 12.4 TARGETED TREATMENT 191 12.5 DOSAGE OF MEDICATION
193 12.6 CHOICE OF MEDICATION 194 12.7 EFFECT OF ANTIPSYCHOTIC DRUGS ON
THE COURSE OF SCHIZOPHRENIA 195 12.8 MAINTENANCE DRUGS AND PSYCHOSOCIAL
TREATMENT 197 12.9 POSTPSYCHOTIC DEPRESSION 198 12.10 SUPERSENSITIVITY
199 - 12.11 CONCLUSION 201 CONTENTS 13 DEPOT NEUROLEPTICS 205 D.A.W.
JOHNSON 13.1 INTRODUCTION 205 13.2 COMPLIANCE 207 13.3 DELIVERY SERVICE
208 13.4 RISK OF SIDE-EFFECTS 209 13.5 CONCLUSIONS 211 14 THE
SIDE-EFFECTS OF ANTIPSYCHOTIC DRUGS. I. CNS AND NEUROMUSCULAR EFFECTS
213 T.R.E. BARNES AND J.G. EDWARDS 14.1 NEUROPSYCHIATRIC EFFECTS 214
14.2 NEUROMUSCULAR EFFECTS 217 14.3 AUTONOMIC EFFECTS 239 15 THE
SIDE-EFFECTS OF ANTIPSYCHOTIC DRUGS. II. EFFECTS ON OTHER 249
PHYSIOLOGICAL SYSTEMS J.G. EDWARDS AND T.R.E. BARNES 15.1 ENDOCRINE AND
METABOLIC DISORDERS 250 15.2 IMMUNOLOGICAL REACTIONS 253 15.3 CUTANEOUS
REACTIONS 253 15.4 OPHTHALMOLOGICAL REACTIONS 255 15.5 HAEMATOLOGICAL
REACTIONS 256 15.6 CARDIAC EFFECTS 258 15.7 RESPIRATORY REACTIONS 260
15.8 GASTROINTESTINAL REACTIONS 260 15.9 HEPATIC REACTIONS 261 15.10
SEXUAL DYSFUNCTION 262 15.11 EFFECTS ON THE EMBRYO AND NEWBORN 265 15.12
DRUG INTERACTIONS 267 - 15.13 CONCLUSIONS 270 INDEX 277
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV009652957 |
| callnumber-first | R - Medicine |
| callnumber-label | RM333 |
| callnumber-raw | RM333.5 |
| callnumber-search | RM333.5 |
| callnumber-sort | RM 3333.5 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 5820 |
| ctrlnum | (OCoLC)29762112 (DE-599)BVBBV009652957 |
| dewey-full | 615/.788 615.5 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.788 615.5 |
| dewey-search | 615/.788 615.5 |
| dewey-sort | 3615 3788 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03254nam a2200553 c 4500</leader><controlfield tag="001">BV009652957</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19940614 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">940614s1993 xx d||| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0120790351</subfield><subfield code="9">0-12-079035-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)29762112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009652957</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM333.5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.788</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.5</subfield><subfield code="2">12a</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5820</subfield><subfield code="0">(DE-625)153018:12926</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antipsychotic drugs and their side effects</subfield><subfield code="c">ed. by Thomas R. E. Barnes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London u.a.</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 287 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Neuroscience perspectives</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most diverse and rapidly changing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological and therapeutic aspects of chosen research areas</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including movement disorders like parkinsonism and akathisia; although, in many cases, these can be minimised by titration to the minimum effective dose</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">However, the introduction of the atypical neuroleptic, clozapine, with a lower liability for motor side-effects, and efficacy for both positive and negative symptoms in patients unresponsive to conventional neuroleptics raised expectations of effective medication with fewer adverse effects. Further, with the identification and characterization of multiple dopamine receptors, the possibility of more selective drugs with an inherently better side-effect potential has arisen</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsicóticos (aplicações terapêuticas)</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsicóticos (farmacologia)</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsychotische geneesmiddelen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bijwerkingen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drogas de abuso (complicações)</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drogas de abuso (efeitos)</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotic Agents</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotic Agents</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antipsychotic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic drugs</subfield><subfield code="x">Complications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Psychotropic drugs</subfield><subfield code="x">Side effects</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakon</subfield><subfield code="0">(DE-588)4047729-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barnes, Thomas R.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006382324&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006382324</subfield></datafield></record></collection> |
| id | DE-604.BV009652957 |
| illustrated | Illustrated |
| indexdate | 2025-02-03T16:22:41Z |
| institution | BVB |
| isbn | 0120790351 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006382324 |
| oclc_num | 29762112 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-578 |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-578 |
| physical | XVI, 287 S. graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Acad. Press |
| record_format | marc |
| series2 | Neuroscience perspectives |
| spellingShingle | Antipsychotic drugs and their side effects Antipsicóticos (aplicações terapêuticas) larpcal Antipsicóticos (farmacologia) larpcal Antipsychotische geneesmiddelen gtt Bijwerkingen gtt Drogas de abuso (complicações) larpcal Drogas de abuso (efeitos) larpcal Antipsychotic Agents adverse effects Antipsychotic Agents pharmacology Antipsychotic Agents therapeutic use Psychotropic drugs Complications Psychotropic drugs Side effects Psychopharmakon (DE-588)4047729-0 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| subject_GND | (DE-588)4047729-0 (DE-588)4003134-2 |
| title | Antipsychotic drugs and their side effects |
| title_auth | Antipsychotic drugs and their side effects |
| title_exact_search | Antipsychotic drugs and their side effects |
| title_full | Antipsychotic drugs and their side effects ed. by Thomas R. E. Barnes |
| title_fullStr | Antipsychotic drugs and their side effects ed. by Thomas R. E. Barnes |
| title_full_unstemmed | Antipsychotic drugs and their side effects ed. by Thomas R. E. Barnes |
| title_short | Antipsychotic drugs and their side effects |
| title_sort | antipsychotic drugs and their side effects |
| topic | Antipsicóticos (aplicações terapêuticas) larpcal Antipsicóticos (farmacologia) larpcal Antipsychotische geneesmiddelen gtt Bijwerkingen gtt Drogas de abuso (complicações) larpcal Drogas de abuso (efeitos) larpcal Antipsychotic Agents adverse effects Antipsychotic Agents pharmacology Antipsychotic Agents therapeutic use Psychotropic drugs Complications Psychotropic drugs Side effects Psychopharmakon (DE-588)4047729-0 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| topic_facet | Antipsicóticos (aplicações terapêuticas) Antipsicóticos (farmacologia) Antipsychotische geneesmiddelen Bijwerkingen Drogas de abuso (complicações) Drogas de abuso (efeitos) Antipsychotic Agents adverse effects Antipsychotic Agents pharmacology Antipsychotic Agents therapeutic use Psychotropic drugs Complications Psychotropic drugs Side effects Psychopharmakon Arzneimittelnebenwirkung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006382324&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT barnesthomasr antipsychoticdrugsandtheirsideeffects |